- Professor Salvatore Cuzzocrea, Ph.D. has been appointed as an independent member of the company’s Board of Directors, effective immediately
- Dr. Cuzzocrea is an acknowledged expert in the science and clinical use of nitric oxide therapy
- Dr. Cuzzocrea has completed numerous studies of R-107, a nasal spray designed to increase the level of nitric oxide present in the nasal cavities
- Claritas Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
- Claritas Pharmaceuticals, Inc. is down 10.0 per cent, trading at C$0.045 per share at 10 am EST
Claritas Pharmaceuticals (KLY) has added Professor Salvatore Cuzzocrea, Ph.D. as an independent member of the company’s board of directors, effective immediately.
Dr. Cuzzocrea is an acknowledged expert in the science and clinical use of nitric oxide therapy, and his appointment to the Board of Directors will position the company as a leader in the field of nitric oxide therapeutics.
“We are delighted to add Dr. Cuzzocrea to the Company’s Board of Directors,” stated Robert Farrell, President and CEO.
“We are eager to begin work with Dr. Cuzzocrea on the development of R-107, our proprietary nitric oxide-releasing compound that is being developed as a treatment for coronavirus, vaccine-resistant COVID-19, and other viral infections.
With his deep experience and knowledge regarding nitric oxide and R-107, he will be a strong strategic resource for Claritas.”
Nitric oxide has been demonstrated to be effective against a wide variety of viruses. Nevertheless, nitric oxide has not been developed as an antiviral agent due to the fact that it is a gas that must be administered by inhalation therapy, which requires special inhalation equipment and administration by trained respiratory therapists.
R-107 is a liquid, nitric oxide-releasing compound designed to overcome these issues. R-107 can be easily administered orally as a capsule, or nasally through the use of a nasal spray, or by injection.
Claritas will not only develop R-107 as a therapy for vaccine-resistant COVID-19 infection but also as a broad-spectrum antiviral drug for the treatment and possible prevention of future viral outbreaks, including viruses that cause influenza and the common cold.
Dr. Cuzzocrea, the former President of the European Shock Society, is an internationally renowned authority and leader on the biology and pathophysiology of nitric oxide. He currently serves in numerous leadership roles at the University of Messina in Sicily, including Professor of Pharmacology at the University’s School of Medicine.
Dr. Cuzzocrea brings expert knowledge of R-107 to Claritas, having carried out more than 40 studies of this molecule in the treatment of experimental models of acute lung injury, pulmonary arterial hypertension, wound healing, ischemia-reperfusion injury, and multiple organ failure in sepsis and endotoxic shock.
Dr. Cuzzocrea is an authority also on the biological mechanisms of cytokine-storm-induced acute lung injury, positioning him to understand the pathophysiology of COVID-19 disease and its amelioration by the supplemental provision of nitric oxide by the administration of R-107.
Claritas Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company developing a portfolio of pharmaceutical products in Canada.
Claritas Pharmaceuticals, Inc. is down 10.0 per cent, trading at C$0.045 per share at 10 am EST.
